Clinical Context
A typical patient is a 65-year-old with relapsed or refractory multiple myeloma who has exhausted standard lines of therapy and is being treated with teclistamab-cqyv as a bispecific T-cell engager given by subcutaneous or intravenous injection per product labeling. The clinical workflow begins with eligibility confirmation (disease progression, prior therapies, performance status), baseline laboratory assessment (CBC, metabolic panel, liver and renal function), infectious disease screening and vaccination review, and informed consent. On treatment day, nursing performs pre-medication (antipyretic, antihistamine, corticosteroid as indicated), verifies the prescribed dose in mg and converts to required vial units of J9380 (each unit = 0.5 mg), obtains baseline vital signs and oxygen saturation, and documents infusion/injection start and stop times. Post-administration monitoring includes vital signs and observation for cytokine release syndrome or immune effector cell-associated neurotoxicity, with empiric management protocols available. Documentation includes drug name teclistamab-cqyv, dosage administered, number of J9380 units billed, lot number, route of administration, administration site, and any applicable modifier(s). Payors involved may include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare depending on patient coverage.